Abstract: The invention relates to transparent therapeutic systems (TTS) which contain the active substance nicotine and which further contain at least one acid amide group as a lateral functional group. The TTS can be transparent and for discreet use. The invention also relates to methods for producing these TTS, said TTS being produced by methods using said polymers and being charged with active substance by way of a printing method.

Abstract: Disclosed is a method for marking film-type dosage forms, comprising at least the positioning of a film-type dosage form between two layers of a sealable packaging material, the sectional heat-sealing of the two layers of the sealable packaging material so as to obtain an edge-sealed bag containing the film-type dosage form, and the blind-embossing of the film-type dosage form contained in the edge-sealed bag through at least one of the two layers of packaging material of the edge-sealed bag.

Abstract: A sealing ring, including at least one sealing element having a first permeation coefficient, and at least one permeation barrier of a thermoplastic material having a second permeation coefficient, wherein the at least one sealing element and the at least one permeation barrier form a unit, and wherein the first permeation coefficient is higher than the second permeation coefficient.

Abstract: The invention relates to a medical product for a fastening duration of at least 7 days having good skin compatibility. The medical product includes a central adhesive compartment (3) and an over-patch. The over-patch is free of active ingredients and is formed from a water-vapor-permeable back layer (1) and an adhesive polymer layer (2) that is free of active ingredients. The invention further relates to a method for the production of the foregoing medical product, and to kits of parts containing laminates of layers 1 and 2.

Abstract: A transdermal therapeutic system for the transdermal administration of buprenorphine comprising a buprenorphine-containing self-adhesive layer structure having (A) a buprenorphine-impermeable backing layer, and (B) a buprenorphine-containing pressure-sensitive adhesive layer on the backing layer. The buprenorphine-containing adhesive layer comprises (a) at least one polymer-based pressure-sensitive adhesive, (b) an analgesically effective amount of buprenorphine base or a pharmaceutically acceptable salt thereof, (c) a viscosity-increasing substance in an amount of about 0.1% to about 8% of the buprenorphine-containing pressure-sensitive adhesive layer, and (d) a carboxylic acid selected from oleic acid, linoleic acid, linolenic acid, levulinic acid and mixtures thereof. The amount of the carboxylic acid is sufficient so that the analgesically effective amount of buprenorphine is solubilized in the carboxylic acid to form a mixture including the viscosity-increasing substance.

Abstract: The present invention relates to a pad printing method for producing an administration form for a pharmaceutical active agent, wherein the method comprises providing a substrate of the administration form and transferring the active agent by means of a pad from a cliché onto the substrate, wherein the area of the cliché is larger than the active-agent-containing area printed onto the substrate. This method is especially suitable for producing transdermal therapeutic systems with volatile active agents. The present invention also relates to arrangements by means of which a method of this kind can be implemented.

Abstract: A keyed-alike digital consumer access key is generated for distribution to a plurality of vehicles of a fleet. The keyed-alike digital consumer access key is deployed to the plurality of vehicles. The keyed-alike digital consumer access key is deployed to a mobile device. A request from a mobile device may be received to gain access to the plurality of vehicles. Responsive to validating the mobile device, the mobile device may be sent the keyed-alike digital consumer access key and a unique identifier corresponding to the mobile device, the keyed-alike digital consumer access key for use by the mobile device in authentication to one or more of the plurality of vehicles, the unique identifier for use by the mobile device in tracking which mobile device is accessing the one or more of the plurality of vehicles.

Abstract: An onboard communication network of a vehicle is monitored to detect a request message that includes a first cipher based message authentication code (CMAC) and a request. A challenge message is determined based on the request message. The challenge message includes a counter and a random number output from a random number generator. A second CMAC is generated based on the challenge message and the request. The request message is authenticated based on determining that the second CMAC matches the first CMAC. The vehicle is operated based on the authenticated request message.

Abstract: The disclosure relates to a testing device for testing tack, including: a test probe which has a test body; and a suspension which guides the test body, the suspension movably supporting the test body. The disclosure further relates to a testing machine for testing tack, including a measuring apparatus and a testing device of this type, which is connected to the measuring apparatus. Finally, the disclosure relates to a method for determining the tack. The method includes the steps of guiding a test probe of a test body onto a sample to be tested, placing the test probe onto the sample, lifting the test probe off of the sample, and sensing the force F as the test probe is lifted off.

Abstract: The present invention relates to a transdermal therapeutic system for the cutaneous administration of phenprocoumon, comprising an active-substance-impermeable backing layer, an adhesive matrix layer and optionally a removable protective layer, the adhesive matrix layer containing phenprocoumon and at least one matrix polymer, and the content of phenprocoumon in the matrix polymer being ?7.5 wt. %. By virtue of the low load, it is ensured that the system releases the active ingredient substantially in high release rates, because high thermodynamic activity of the active ingredient is achieved. The present invention also relates to a method for producing a corresponding transdermal therapeutic system.

Abstract: A keyed-alike digital consumer access key is generated for distribution to a plurality of vehicles of a fleet. The keyed-alike digital consumer access key is deployed to the plurality of vehicles. The keyed-alike digital consumer access key is deployed to a mobile device. A request from a mobile device may be received to gain access to the plurality of vehicles. Responsive to validating the mobile device, the mobile device may be sent the keyed-alike digital consumer access key and a unique identifier corresponding to the mobile device, the keyed-alike digital consumer access key for use by the mobile device in authentication to one or more of the plurality of vehicles, the unique identifier for use by the mobile device in tracking which mobile device is accessing the one or more of the plurality of vehicles.

Abstract: Exemplary embodiments described in this disclosure are generally directed to systems and methods for securely creating passwords for performing various keyless operations upon a vehicle. In an exemplary method, a computer receives a request for creating a password for a phone-as-a-key (PaaK) device. The computer determines that the PaaK device is present inside the vehicle and that the vehicle engine has been placed in an accessory state or a run state by an authorized PaaK device located in the vehicle. The computer further determines that a passive entry passive start (PEPS) key fob is present inside the vehicle. A prompt is provided for entry of a password. The computer checks to determine if an entered password has been already assigned to another PaaK device. If unassigned, the computer links the password to the PaaK device and authorizes the entered password as a valid keyless starting password for the vehicle.

Abstract: A system includes a vehicle, a first passive Near-Field Communication (NFC) device, and a first mobile device communicatively coupled to the vehicle and including a digital vehicle key. The first mobile device distributes the digital vehicle key to the first passive NFC device and informs the vehicle an instance in which the mobile device has distributed the digital vehicle key to the first passive NFC device.

Abstract: Exemplary embodiments described in this disclosure are generally directed to systems and methods for securely creating passwords for performing various keyless operations upon a vehicle. In an exemplary method, a computer receives a request for creating a password for a phone-as-a-key (PaaK) device. The computer determines that the PaaK device is present inside the vehicle and that the vehicle engine has been placed in an accessory state or a run state by an authorized PaaK device located in the vehicle. The computer further determines that a passive entry passive start (PEPS) key fob is present inside the vehicle. A prompt is provided for entry of a password. The computer checks to determine if an entered password has been already assigned to another PaaK device. If unassigned, the computer links the password to the PaaK device and authorizes the entered password as a valid keyless starting password for the vehicle.

Abstract: A sealing for arrangement between a wall and a wall covering includes a sealing sheet and an adhesive tape. The sealing sheet and the adhesive tape each have a carrier layer of a preferably closed-cell foam plastic. Furthermore, the sealing sheet can bear a nonwoven fabric preferably on the wall-facing side, wherein border strips remain free of the nonwoven fabric for underlapping with an adhesive tape.

Abstract: The invention relates to a transdermal therapeutic system (TTS), comprising a backing layer, which is permeable to the active ingredient, at least one matrix layer, comprising fentanyl or an active agent analogous to fentanyl, based on polyacrylate and a protective layer to be removed before usage, characterized in that the polyacrylate polymer is self-adhesive, free of carboxyl groups, has a saturation solubility for fentanyl of 3 to 20 wt. %, preferably of 4 to 12 and particularly of 5 to 10 wt. % and the layers contain at least 80% of the included active ingredient in a molecularly-dispersed, dissolved form.

Abstract: Exemplary embodiments described in this disclosure are generally directed to systems and methods for ensuring password security when starting a vehicle having a keyless engine starting system. In an exemplary method, a computer detects a depression of an engine start push button when no phone-as-a-key (PaaK) device or passive-entry-passive-start (PEPS) key fob is present in the vehicle. The computer responds by executing a verification procedure prior to password validation. The verification procedure can include operations such as determining that no PaaK device or PEPS key fob is present either inside the vehicle or within a defined geofence outside the vehicle. If the verification procedure is successful, the computer displays a prompt upon a display screen for entering of a password. The computer then uses various security measures when verifying the validity of an entered password, followed by displaying of a message indicating acceptance or rejection of the password.

Abstract: Disclosed are stable dosage forms for oral administration of active pharmaceutical ingredients in which any unpleasant taste sensation, caused by release of the active pharmaceutical ingredient and/or of the excipients in the oral and pharyngeal cavity of the patient, is masked by the use of theobromine-free cocoa.

Abstract: The invention relates to transdermal therapeutic system for the transdermal administration of buprenorphine, comprising a buprenorphine-containing self-adhesive layer structure comprising A) a buprenorphine-impermeable backing layer, and B) a buprenorphine-containing pressure-sensitive adhesive layer on said buprenorphine-impermeable backing layer, the adhesive layer comprising a) at least one polymer-based pressure-sensitive adhesive, b) an analgesically effective amount of buprenorphine base or a pharmaceutically acceptable salt thereof, c) a viscosity-increasing substance in an amount of about 0.

Abstract: The invention relates to transdermal therapeutic system for the transdermal administration of buprenorphine, comprising a buprenorphine-containing self-adhesive layer structure comprising A) a buprenorphine-impermeable backing layer, and B) e a buprenorphine-containing pressure-sensitive adhesive layer on said buprenorphine-impermeable backing layer, the adhesive layer comprising a) at least one polymer-based pressure-sensitive adhesive, b) an analgesically effective amount of buprenorphine base or a pharmaceutically acceptable salt thereof and c) a carboxylic acid selected from the group consisting of oleic acid, linoleic acid and linolenic acid, levulinic acid and mixtures thereof, in an amount sufficient so that said analgesically effective amount of buprenorphine is solubilized therein to form a mixture, and the carboxylic acid buprenorphine mixture forms dispersed deposits in the said pressure-sensitive adhesive, wherein said buprenorphine-containing pressure-sensitive adhesive layer is the skin contact